Compare JAZZ & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JAZZ | EVR |
|---|---|---|
| Founded | 2003 | 1995 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.8B |
| IPO Year | 2007 | 2006 |
| Metric | JAZZ | EVR |
|---|---|---|
| Price | $180.50 | $276.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $215.92 | ★ $345.67 |
| AVG Volume (30 Days) | ★ 966.4K | 628.2K |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.22% |
| EPS Growth | N/A | ★ 54.74 |
| EPS | N/A | ★ 14.05 |
| Revenue | $1,618,693,000.00 | ★ $3,880,084,000.00 |
| Revenue This Year | $6.17 | $22.35 |
| Revenue Next Year | $7.66 | $13.37 |
| P/E Ratio | ★ N/A | $19.59 |
| Revenue Growth | N/A | ★ 29.49 |
| 52 Week Low | $95.49 | $148.63 |
| 52 Week High | $198.00 | $388.71 |
| Indicator | JAZZ | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 34.49 |
| Support Level | $176.67 | $238.96 |
| Resistance Level | $182.99 | $320.26 |
| Average True Range (ATR) | 4.97 | 12.42 |
| MACD | -1.09 | -1.36 |
| Stochastic Oscillator | 25.88 | 18.15 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. Evercore operates globally, with a particularly strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.